Hunan Hansen Pharmaceutical Co Ltd

Hunan Hansen Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 4.58, indicating that it has sufficient current assets to cover its current liabilities. The company's liquidity_fpt score suggests that it is well-positioned to meet short-term obligations without significant financial strain. However, the risk assessment notes that net cash is negative after subtracting total debt, which could signal potential liquidity challenges if cash flow were to decline. In terms of profitability, the company reported a net income of CNY 198.12 million and a return on equity (ROE) of 8.32%, which is a measure of how effectively the company is using shareholders' equity to generate profits. The return on assets (ROA) of 7.36% indicates that the company is generating a solid return on its total assets. These metrics are in line with the industry's preferred profitability indicators, suggesting that the company is performing at or near the industry median. The company's revenue is primarily concentrated in its domestic market, with a significant portion of its sales coming from within China. The company's exposure to geographic markets is not diversified, which could pose a risk if the domestic market experiences economic downturns or regulatory changes. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.03, indicating that it is not heavily leveraged and has a strong equity base. Looking at the company's growth trajectory, the outlook for the current fiscal year is positive, with expected revenue growth driven by increased demand for its pharmaceutical products. The company's capital expenditure for the period was CNY -11.10 million, which suggests that it is not currently investing heavily in new projects or infrastructure. The company's free cash flow of CNY 226.58 million indicates that it has sufficient cash to fund operations and potentially return value to shareholders. The risk assessment highlights that the company's liquidity is rated as medium, and the potential for dilution is low. The company's capital structure is stable, and there are no immediate signs of financial distress. However, the negative net cash position after subtracting total debt is a concern that should be monitored. The company has not made any significant recent announcements or filings that would indicate a change in its strategic direction or financial health.